[{"id":"eb87323c-0942-4abb-b43f-af01b1dff7f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT06015880","created_at":"2023-12-26T19:17:43.252Z","updated_at":"2025-02-25T17:32:19.406Z","phase":"Phase 1","brief_title":"Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","source_id_and_acronym":"NCT06015880","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IFNG • CD79B • CD4","pipe":" | ","alterations":" CD79B expression","tags":["IFNG • CD79B • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD79B expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lenalidomide • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/20/2024","start_date":" 05/20/2024","primary_txt":" Primary completion: 06/29/2026","primary_completion_date":" 06/29/2026","study_txt":" Completion: 06/29/2026","study_completion_date":" 06/29/2026","last_update_posted":"2025-01-30"}]